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A B S T R A C T
Purpose: In a signiﬁcant number of patients developing epilepsy in adult life, the aetiology of their
seizures remains unclear. Antibodies directed against the voltage gated potassium channel complex
(VGKC Ab) have been identiﬁed in various cohorts of patients with epilepsy, although the role of these
antibodies in epilepsy pathogenesis is not fully known.
Method: We reviewed the notes of 144 patients with unexplained adult onset epilepsy who had been
tested for VGKC Abs. We collected data on their clinical syndrome, investigation results and response to
treatment.
Results: We identiﬁed 6 (4.2%) patients who had titres of >400 pM. One of the six patients was positive for
LGI1 and another for CASPR2 subunit antibodies. All patients were given immunotherapy and experienced
improvement in seizure control. No patient had the clinical syndrome of limbic encephalitis.
Conclusion: Patients with otherwise unexplained epilepsy and positive VGKC Abs are a heterogeneous
group. In our cohort there was an overall favourable response to immunotherapy but further prospective
studies are needed to determine the signiﬁcance of these antibodies and the optimum treatment
regimen for patients.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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A signiﬁcant number of patients develop epilepsy in adult life,
but identiﬁcation of epileptogenic abnormalities with brain
imaging techniques is possible only in a proportion of patients.1
A large number of patients with refractory epilepsy also have no
identiﬁable structural abnormalities.2 In recent years, a number of
studies have found antibodies directed against neuronal cell
surface antigens in patients with epilepsy. These include anti-
bodies against the voltage-gated potassium channel complex
(VGKC Abs) and the N-methyl-D-aspartate (NMDA) glutamate
receptor.4–6 The role of these antibodies in the pathogenesis of
epilepsy has not been fully established. Brenner et al. found that
VGKC Abs were signiﬁcantly more likely to occur in patients with
focal epilepsy of undetermined cause than in patients with
structural/metabolic focal epilepsy.6 Their study also suggests
that the presence of neuronal antibodies in newly diagnosed
epilepsy may be associated with a reduced chance of seizure
freedom with antiepileptic drug therapy alone. Neurological* Corresponding author at: Department of Neurology, Salford Royal Hospital NHS
Foundation Trust, Stott Lane, Salford, M6 8HD, United Kingdom.
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cell surface antigens often respond to immunotherapy. Therefore,
in patients with epilepsy, identiﬁcation of these antibodies could
have important therapeutic implications.
Since January 2010, we have tested all adult patients attending
our epilepsy service with ‘otherwise unexplained’ adult onset
epilepsy for the presence of VGKC Abs, as well as antibodies to
NMDA receptor and glutamate decarboxylase (GAD). We describe
a cohort of patients with adult onset cryptogenic focal epilepsy in
whom VGKC Abs were detected.
2. Methods
We reviewed the notes of patients seen between January 2010
and February 2012 in two hospitals in Greater Manchester,
England, who had been tested for the presence of VGKC Abs,
following presentation with ‘unexplained adult onset epilepsy.’
This was deﬁned as focal or unclassiﬁed epilepsy, with onset in
adult life in patients with no history of cerebral insults and no
epileptogenic lesions identiﬁed on MRI scanning using appropriate
imaging protocols. Patients with clearly deﬁned idiopathic
generalised epilepsy syndromes and symptomatic epilepsies were
not included.
Previous studies have shown VGKC Ab can be found in up to 5%
of adult controls at titres between 100 and 400 pM.5 Patients withvier Ltd. All rights reserved.
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testing for antibodies to leucine-rich glioma inactivated protein 1
(LGI1) and contactin associate protein-like 2 (CASPR2). All testing
was performed at the neuroimmunology laboratory at the
University of Oxford, using previously described methods of
testing for VGKC complex, LGI1 and CASPR2 subunit antibodies.7–9
Samples were sent to the laboratory over the study period, and not
tested as a single batch. Patients with VGKC Ab >400 pM were
offered immunotherapy with corticosteroids, and subsequently
azathioprine where felt appropriate by the treating clinician.
Details of treatments including immunotherapy, changes in
seizure frequency and VGKC Ab titres were recorded at monthly
clinical review by one of the authors. Demographic and clinical
details, investigation results and response to treatment were
collated by review of notes.
3. Results
144 patients were tested for VGKC Abs between January 2010
and February 2012. This yielded 11 patients (8%) with positive
VGKC Ab (>100 pM) of which 6 patients (4.2%) had titres >400 pM.
Of the 5 patients with VGKC Ab titres between 100 and 400 pM,
one was negative on repeat testing subsequently, and another
showed persistent low titre. The remaining three patients became
seizure free and did not have the test repeated. The characteristics
of patients with VGKC Ab titres >400 pM are summarised in
Table 1
Of the 6 patients with VGKC Ab titres >400 pM, 5 were male. The
mean age was 52.5 (27–77) years. The mean period between onset of
epilepsy and identiﬁcation of VGKC Abs was 11.5 (0.6–24.0) months.
Seizures in all patients were classiﬁed as focal seizures and in 4
patients the seizure focus was clinically felt to be the temporal lobe.
Semiological features in these patients included rising abdominal
sensation, olfactory hallucination, piloerection, de´ja` vu, jamais vu,
oromasticatory automatisms, and depersonalisation. Two patients
experienced generalised tonic clonic seizures (GTCS) in addition to
focal seizures. One patient (Patient E) had faciobrachial dystonic
seizures (FBDS), recently described in association with LGI1Table 1
Clinical and demographic characteristics of 6 patients with epilepsy and VGKC Ab (GTCS
intravenous methylprednisolone).
Patient A Patient B 
Demographics 36-Year-old female 67-Year-old male 
Duration of epilepsy
prior to identiﬁcation
of VGKC Ab
4.9 months 0.6 months 
Seizure types GTCS and focal seizures
(temporal lobe)
Focal seizures
(temporal lobe)
Initial MRI Brain Normal Increased signal
in left hippocampus
and amygdala
CT scan body/PET* Prominent thymus Normal* 
CSF Normal Normal 
VGKC complex subunit
antibodies
LGI1 – Negative
CASPR2 –
Negative
LGI1 – Negative
CASPR2 – Negative
Treatment – AEDs Lamotrigine Lamotrigine, Valproate,
Clobazam
Treatment – immunotherapy IVMP then prednisolone.
Azathioprine
Prednisolone.
Azathioprine
Response to immunotherapy VGKC Ab titre remains
elevated. Seizure
frequency improved
VGKC Ab titre fell
rapidly. Seizure freeantibodies,9 which were detected in this patient. No patient had
the clinical syndrome of limbic encephalitis (LE) characterised by
amnesia, encephalopathy, personality change or psychosis and
seizures. No patient had hyponatraemia at the time of VGKC Ab
testing.
VGKC Ab titres at initial testing ranged from 180 to 3450 pM. In
Patient A (initial VGKC Ab titre 180 pM) the titre rose to >400 pM
on repeat testing at a later date. The sera of all 6 patients were
tested for the presence of LGI1 and CASPR2 antibodies. Patient E
(who presented with FBDS) was positive for LGI1 subunit
antibodies. Patient C was positive for CASPR2 antibodies. All other
patients were negative for both LGI1 and CASPR2 antibodies.
MRI imaging of the brain was normal in all patients except
Patient B, in whom increased signal in the left hippocampus and
amygdala was noted at the time of diagnosis and initially
attributed to recent seizures. Repeat MRI imaging 12 months
later showed volume loss and high signal in the left mesial
temporal lobe, consistent with left mesial temporal sclerosis, in
spite of immunotherapy and suppression of VGKC Ab titres to
undetectable levels, and control of seizures (Fig. 1).
Four patients had CSF analysis. This was normal in two patients
and in two other patients marginally elevated CSF protein levels
were seen (0.50–0.53 g/L). CSF analysis for VGKC Ab and
oligoclonal bands were negative in all four patients. Patients B,
C and E had at least one EEG. No interictal or ictal abnormalities
were noted, including during FBDS in Patient E. All patients had
whole body CT scan, and two patients had FDG-PET scan, with no
evidence of malignancy identiﬁed. Patient A, a 35-year-old female,
had persistent thymic prominence on CT scan. Removal of the
thymus did not result in signiﬁcant fall in VGKC Ab titre in this
patient. Histological examination showed thymic hyperplasia, and
no evidence of thymoma.
All patients apart from Patient F initially received treatment
with standard ﬁrst line antiepileptic drugs (AEDs) for focal epilepsy
with a partial reduction in seizure frequency observed. Patient F
was tested for VGKC Ab at presentation, and was initiated on
immunotherapy prior to commencing AEDs. AED therapy was
subsequently used, but failed to produce complete seizure control. – generalised tonic clonic seizures, FBDS – faciobrachial dystonic seizures, IVMP –
Patient C Patient D Patient E Patient F
77-Year-old male 51-Year-old male 57-Year-old
male
27-Year-old male
2.0 months 24.0 months 14.3 months 23.3 months
Focal seizures
(temporal lobe)
Focal seizures
(temporal lobe)
FBDS GTCS and focal
seizures
(extratemporal)
Normal Normal Normal Normal
Normal Normal* Normal Normal
Protein 0.50 g/L Protein 0.53 g/L Not Done Not done
LGI1 – Negative
CASPR2 – Positive
LGI1 – Negative
CASPR2 – Negative
LGI1 – Positive
CASPR2 –
Negative
LGI1 – Negative
CASPR2 –
Negative
Lamotrigine,
Levetiracetam
Lamotrigine Carbamazepine Lamotrigine
IVMP then
prednisolone
Prednisolone.
Azathioprine
Prednisolone Prednisolone
VGKC Ab titre fell
rapidly, but
subsequently
increased.
Seizure free
VGKC Ab titre fell
gradually. Seizure
frequency improved
VGKC Ab titre
fell rapidly.
Seizure free
Did not tolerate
steroids. VGKC Ab
titre remains
elevated. Seizure
free period but
recent recurrence
Fig. 1. Coronal FLAIR images in radiological convention showing evolution of MRI changes in Patient B. The left hippocampus shows increased signal at presentation (left).
Following treatment with steroids and Azathioprine and with improvement in seizure control and VGKC Ab becoming undetectable, repeat MRI scan 12 months later (right)
shows volume loss in the left hippocampus consistent with hippocampal sclerosis.
Fig. 2. Changes in VGKC Ab titres, seizure frequency and immunotherapy received in 6 patients with VGKC Ab associated epilepsy. Follow up in months is shown on the X axis.
Percentage change in seizure frequency is represented in solid diamonds and on the Y axis on the left with 100% representing seizure freedom. VGKC Ab titres (pM) are
represented in open circles, and on the Y axis on the right. Steroid therapy (prednisolone) is shown in hatched bars, and azathioprine treatment is shown in the solid black
bars. The initial daily dose for prednisolone was 60 mg in all patients, and subsequent doses are shown as a proportion of the initial dose. The azathioprine doses ranged from
25 mg to 150 mg per day, and are not shown to scale.
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the identiﬁcation of VGKC Abs. Intravenous methylprednisolone
was used initially in Patients A and C, and oral prednisolone in
others. Patients A, B and D also received azathioprine. The dosing
information for steroids and azathioprine is presented in Fig. 2.
Changes in VGKC Ab titre and seizure frequency during immuno-
therapy in each of the 6 patients is depicted in Fig. 2. All patients
showed marked improvement in seizure control, with three patients
achieving seizure freedom. Patient F discontinued steroid therapy
due to adverse effects, and suffered recurrence of seizures. There was
however no consistent correlation between fall in VGKC Ab titres
and improvement in seizure control.
4. Discussion
It is likely that autoimmune processes, speciﬁcally the
generation of antibodies to neuronal surface antigens underlie
some epilepsies.6,10–13,17 Voltage gated potassium channels are of
interest in epilepsy, as they play an important role in regulating
neuronal excitability. In this cohort of 144 adult patients withotherwise unexplained epilepsy, 6 (4.2%) had signiﬁcant titres of
VGKC Abs. Three previous studies have reported a prevalence of
VGKC Ab in 6%, 5% and 11% respectively in cohorts of patients with
epilepsy, but these authors included all patients with VGKC Ab
titres >100 pM.3,6,11 We have restricted our analysis to patients
with titres >400 pM as lower titres can be present in up to 5% of
adult controls, and does not reliably distinguish patients with
neurological disorders.7
The VGKC Ab positive patients in our cohort are a heteroge-
neous group, both serologically and clinically. Two patients had
antibodies against speciﬁc neuronal surface targets (LGI1 and
CASPR2) and one conforms to the recently described FBDS
phenotype. The other patients had strongly positive VGKC Ab,
but the speciﬁc antigenic target is unknown. One patient (B) had
MRI changes consistent with LE yet lacked the typical clinical
symptoms of amnesia, encephalopathy, behavioural change and
temporal lobe seizures. In no patient was an underlying tumour
discovered, and one patient had thymic hyperplasia. All our
patients had improvement in seizure control with immunothera-
py, although not all have been rendered seizure free. The antibody
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in response to immunotherapy. Despite this the overall favourable
response to immunosuppression, in patients for whom AEDs alone
were not achieving seizure freedom, supports the concept of
immune mediated epilepsy in this group. Zuliani et al. have
proposed criteria for diagnosis of neuronal surface antibody
associated neurological syndromes (NSAS).15 Although only one
of our patients had evidence of CNS inﬂammation on imaging, the
presence of VGKC Ab (an NSAb) and the good response to
immunotherapy indicates that VGKC Ab associated epilepsy is a
NSAS.
It could be postulated that VGKC Abs are not primarily
pathogenic, but occur as a secondary response to neuronal damage
relating to seizures. However, the good clinical response to
immunotherapy, which, in Patients B, C, E and less so in D,
mirrored the fall in antibody titre indicates a pathogenic role for
VGKC Ab in our patients. Another possibility is that VGKC Ab
associated epilepsy is part of a spectrum of VGKC Ab mediated CNS
disorders, which includes LE and Morvans syndrome, or the acute
phase of an autoimmune illness which can evolve into chronic
temporal lobe epilepsy, as has been suggested by Bien et al.14 None
of our patients however had the full clinical syndrome of LE, or
hyponatraemia, which has been described in patients with VGKC
Ab associated LE in 59–80% of cases5,8. In this regard, our patients
bear similarity to patients with FBDS, none of whom had
hyponatraemia in a series of 13 cases.10 Additionally, in most
cases of VGKC Ab mediated LE, VGKC Ab is directed against the
LGI1 subunit.8,16 LGI1 subunit antibodies were found in only one of
our patients, CASPR2 subunit antibodies were found in one other
and the other 4 patients negative for both. In the study by Brenner
et al., only one of 20 patients with epilepsy testing positive for
VGKC Ab had antibodies to LGI1, and no patient had CASPR2
antibodies. It is likely therefore that the VGKC Abs in patients with
epilepsy is directed against another component of the VGKC
complex. This suggests that VGKC Ab associated epilepsy may be a
distinct clinicoimmunological syndrome from VGKC Ab
mediated LE.
This is a retrospective review of clinical cases and therefore
there are limitations to the conclusions that can be drawn. Not all
patients had lumbar punctures and detailed neuropsychology was
not carried out at the time of presentation in all cases. The antibody
testing was carried out in a clinical and pragmatic way, with sera
being ‘screened’ initially for the presence of VGKC Ab and only the
strongly positive cases further tested for LGI1 and CASPR2
antibodies. Our testing paradigm would not have identiﬁed
patients with LGI1 and CASPR2 antibodies without being strongly
positive for VGKC Ab. However, our results add to a growing body
of evidence pointing to antibodies to neuronal surface antigens
underlying some epilepsies, and indicates the need for further
studies. Efforts should focus on identifying the antigenic target in
patients with VGKC Ab associated epilepsy, but test negative forLGI1 and CASPR2 antibodies. While corticosteroid treatment
appeared to beneﬁt our patients, the most appropriate form and
duration of immunotherapy for patients with epilepsy and VGKC
Abs remain to be identiﬁed.
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